Estévez-Loureiro Rodrigo, Benito-González Tomás, Garrote-Coloma Carmen, Fernández-Vázquez Felipe, Avanzas Pablo, Piñón Miguel, Pascual Isaac
Interventional Cardiology Unit, Hospital Álvaro Cunqueiro, Vigo, Spain.
Interventional Cardiology Unit, Complejo Asistencial Universitario de Leon, Spain.
Ann Transl Med. 2020 Aug;8(15):963. doi: 10.21037/atm.2020.03.154.
Mitral regurgitation (MR) is the second most common valvular heart disease and its prevalence is increasing with population ageing. In the recent years we have witnessed the development of several transcatheter devices to correct MR in patients at high-risk for surgery. The majority of evidence regarding safety and efficacy of this new therapy comes from MitraClip studies. However, new alternatives on the field of valve repair have emerged with promising results. The aim of this review is to portrait the landscape of transcatheter mitral repair alternatives, from currently used devices to those that will have a role in the near future.
二尖瓣反流(MR)是第二常见的心脏瓣膜疾病,其患病率随着人口老龄化而增加。近年来,我们见证了几种经导管装置的发展,用于纠正手术高危患者的二尖瓣反流。关于这种新疗法安全性和有效性的大多数证据来自MitraClip研究。然而,瓣膜修复领域出现了新的替代方案,并取得了令人鼓舞的结果。本综述的目的是描绘经导管二尖瓣修复替代方案的全景,从目前使用的装置到在不久的将来将发挥作用的装置。